Related references
Note: Only part of the references are listed.Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells
Zhuo-Xun Wu et al.
FRONTIERS IN PHARMACOLOGY (2021)
Potential Therapeutic Targets of Quercetin, a Plant Flavonol, and Its Role in the Therapy of Various Types of Cancer through the Modulation of Various Cell Signaling Pathways
Saleh A. Almatroodi et al.
MOLECULES (2021)
Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance
Ming Li et al.
CELL DEATH & DISEASE (2021)
Design, synthesis and molecular docking study of new purine derivatives as Aurora kinase inhibitors
Mohamed E. Khalifa
JOURNAL OF MOLECULAR STRUCTURE (2021)
Aurora Kinase B Expression, Its Regulation and Therapeutic Targeting in Human Retinoblastoma
Naheed Arfin Borah et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2021)
Effect of CCT137690 on long non-coding RNA expression profiles in MCF-7 and MDA-MB-231 cell lines
Tugce Balci Okcanoglu et al.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES (2020)
Augmentation of danusertib's anticancer activity against melanoma by blockage of autophagy
Yuan-Yuan Shang et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2020)
AURKB promotes gastric cancer progression via activation of CCND1 expression
Min Nie et al.
AGING-US (2020)
Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis
Jue Jiang et al.
CANCER CELL (2020)
Regulation of cell cycle by MDM2 in prostate cancer cells through Aurora Kinase-B and p21WAF1/CIP1 mediated pathways
Thanigaivelan Kanagasabai et al.
CELLULAR SIGNALLING (2020)
Aurora B kinase is recruited to multiple discrete kinetochore and centromere regions in human cells
Amanda J. Broad et al.
JOURNAL OF CELL BIOLOGY (2020)
Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights
Mohammad M. Al-Sanea et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity
Italo Antonio Fernandes et al.
MOLECULES (2020)
Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition
Min Huang et al.
ONCOGENE (2020)
Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
Naga Rajiv Lakkaniga et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B
Tomoya Takeda et al.
ONCOLOGY REPORTS (2020)
RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis
Sara Sanchez-Molina et al.
SCIENCE ADVANCES (2020)
Structure-Based Discovery and Bioactivity Evaluation of Novel Aurora-A Kinase Inhibitors as Anticancer Agents via Docking-Based Comparative Intermolecular Contacts Analysis (dbCICA)
Majd S. Hijjawi et al.
MOLECULES (2020)
Promising Therapy in Lung Cancer: Spotlight on Aurora Kinases
Domenico Galetta et al.
CANCERS (2020)
HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E
Xiaoyu Chang et al.
THERANOSTICS (2020)
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma
Nicolas Floc'h et al.
MOLECULAR CANCER THERAPEUTICS (2019)
FBXW7 in Cancer: What Has Been Unraveled Thus Far?
Bethsebie Lalduhsaki Sailo et al.
CANCERS (2019)
High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma
Sarah Wang et al.
CLINICAL CANCER RESEARCH (2019)
A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
Melissa Lynne Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines
Di Huang et al.
CANCER CELL INTERNATIONAL (2019)
Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells
Muhammad Furqan et al.
CELL CYCLE (2019)
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Jordi Bertran-Alamillo et al.
NATURE COMMUNICATIONS (2019)
Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms
Keli Lima et al.
SCIENTIFIC REPORTS (2019)
Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide
Wahafu Alafate et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naive or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy
William B. Donnellan et al.
BLOOD (2019)
Aurora kinase B inhibitor barasertib (AZD1152) inhibits glucose metabolism in gastric cancer cells
Jian He et al.
ANTI-CANCER DRUGS (2019)
A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia
Hartmut Doehner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Aurora B kinase activity-dependent and -independent functions of the chromosomal passenger complex in regulating sister chromatid cohesion
Qi Yi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
Matthew G. Oser et al.
CANCER DISCOVERY (2019)
Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells
Sandhya Noronha et al.
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL (2018)
Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer
Swatishree Sradhanjali et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2018)
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
Michael Carducci et al.
INVESTIGATIONAL NEW DRUGS (2018)
A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor
Qiaohua Zhu et al.
JOURNAL OF CANCER (2018)
Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes
Marc Payton et al.
MOLECULAR CANCER THERAPEUTICS (2018)
The functional diversity of Aurora kinases: a comprehensive review
Estelle Willems et al.
CELL DIVISION (2018)
An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression
Jaewook Ryu et al.
CANCER MEDICINE (2018)
Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma
Sonali Kumari et al.
NANOMEDICINE (2018)
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
B. Vormoor et al.
PEDIATRIC BLOOD & CANCER (2017)
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles
Nicolas Floc'h et al.
MOLECULAR CANCER THERAPEUTICS (2017)
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Zefang Tang et al.
NUCLEIC ACIDS RESEARCH (2017)
Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: A potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions
Swatishree Sradhanjali et al.
PLOS ONE (2017)
Aurora kinases: novel therapy targets in cancers
Anqun Tang et al.
ONCOTARGET (2017)
Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer
Christopher C. Mills et al.
CANCER RESEARCH (2017)
A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia
Janna K. Duong et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia
Hagop M. Kantarjian et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Aurora B Inhibitor TAK-901 Synergizes with BCL-xL Inhibition by Inducing Active BAX in Cancer Cells
Saomi Murai et al.
ANTICANCER RESEARCH (2017)
Aurora B expression modulates paclitaxel response in non-small cell lung cancer
Ahmed S. K. Al-Khafaji et al.
BRITISH JOURNAL OF CANCER (2017)
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
Annette E. Hay et al.
LEUKEMIA & LYMPHOMA (2016)
A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
Klaus Mross et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells
Si-Jia He et al.
CANCER LETTERS (2016)
Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo
Barbara A. Helfrich et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Quercetin suppresses lung cancer growth by targeting Aurora B kinase
Zhu Xingyu et al.
CANCER MEDICINE (2016)
Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line
Chiara Tuccilli et al.
ENDOCRINE (2016)
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells
Stine Hole et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
Graham P. Collins et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Gautam Borthakur et al.
HAEMATOLOGICA (2015)
Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells
Dan Zi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Spatial Compartmentalization Specializes the Function of Aurora A and Aurora B
Si Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Discovery of N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines
Stephanie Geuns-Meyer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells
Jin-Ping Li et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells
Chun-Xiu Yuan et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells
Yong-Hui Ding et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma
Roberto Jose Diaz et al.
Oncotarget (2015)
EBNA3C regulates p53 through induction of Aurora kinase B
Hem C. Jha et al.
ONCOTARGET (2015)
Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma
Dominik Bogen et al.
ONCOTARGET (2015)
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Gautam Borthakur et al.
HAEMATOLOGICA (2015)
A Cell Biologist's Field Guide to Aurora Kinase Inhibitors
Christian O. de Groot et al.
FRONTIERS IN ONCOLOGY (2015)
A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
Lucas Moreno et al.
CLINICAL CANCER RESEARCH (2015)
p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma
Zhen Li et al.
MOLECULAR CANCER RESEARCH (2015)
Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma
Nan Li et al.
MOLECULAR CANCER THERAPEUTICS (2015)
AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy
Ali Zekri et al.
TUMOR BIOLOGY (2015)
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity
Oliver Ou et al.
CANCER LETTERS (2014)
Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins
Carolien Boeckx et al.
CANCER LETTERS (2014)
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia
Antonino Maria Sparta et al.
CELL CYCLE (2014)
A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis
James Foran et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines
Enke Baldini et al.
ENDOCRINE-RELATED CANCER (2014)
RASSF tumor suppressor gene family: Biological functions and regulation
Natalia Volodko et al.
FEBS LETTERS (2014)
Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling
Jing Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy
Yan Wang et al.
MOLECULAR CANCER (2014)
Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells
Anna L. Illert et al.
PLOS ONE (2014)
Inhibition of Aurora-B suppresses osteosarcoma cell migration and invasion
Xiao Ping Zhu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2014)
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
Hielke J. Meulenbeld et al.
BJU INTERNATIONAL (2013)
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53
Ondrej Kalous et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia
Hagop M. Kantarjian et al.
CANCER (2013)
Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells
Takahiro Yamauchi et al.
CANCER SCIENCE (2013)
Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
Hagop M. Kantarjian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
Gary K. Schwartz et al.
INVESTIGATIONAL NEW DRUGS (2013)
NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies
S. F. Dent et al.
INVESTIGATIONAL NEW DRUGS (2013)
Aurora B and Kif2A control microtubule length for assembly of a functional central spindle during anaphase
Ryota Uehara et al.
JOURNAL OF CELL BIOLOGY (2013)
Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target
S. A. Hartsink-Segers et al.
LEUKEMIA (2013)
The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines
Lifang Xie et al.
MELANOMA RESEARCH (2013)
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
H. -T. Arkenau et al.
ANNALS OF ONCOLOGY (2012)
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2012)
Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
Mike Dennis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
FBXW7 is involved in Aurora B degradation
Chieh-Lin Teng et al.
CELL CYCLE (2012)
Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model
Katharina Fraedrich et al.
CLINICAL CANCER RESEARCH (2012)
AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas
Wenqing Qi et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells
Kleiton Silva Borges et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)
Fei Fei et al.
MOLECULAR CANCER (2012)
Enhancing Chemosensitivity in ABCB1-and ABCG2-Overexpressing Cells and Cancer Stem-like Cells by An Aurora Kinase Inhibitor CCT129202
Chao Cheng et al.
MOLECULAR PHARMACEUTICS (2012)
Evolution of Resistance to Aurora Kinase B Inhibitors in Leukaemia Cells
Timothy W. Failes et al.
PLOS ONE (2012)
Aurora B kinase phosphorylates and instigates degradation of p53
Chris P. Gully et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
D. S. Boss et al.
ANNALS OF ONCOLOGY (2011)
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
Bob Lowenberg et al.
BLOOD (2011)
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
A. Azzariti et al.
BRITISH JOURNAL OF CANCER (2011)
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
Anne M. Traynor et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide
Loredana Santo et al.
CLINICAL CANCER RESEARCH (2011)
Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
G. Portella et al.
CURRENT MEDICINAL CHEMISTRY (2011)
AURORA B EXPRESSION AS A PROGNOSTIC INDICATOR AND POSSIBILE THERAPEUTIC TARGET IN ORAL SQUAMOUS CELL CARCINOMA
G. Pannone et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2011)
Aurora B Interacts with NIR-p53, Leading to p53 Phosphorylation in Its DNA-binding Domain and Subsequent Functional Suppression
Liming Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
Kosuke Tsuboi et al.
LEUKEMIA RESEARCH (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro
Stefan Balabanov et al.
PLOS ONE (2011)
Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer
A. Pohl et al.
PHARMACOGENOMICS JOURNAL (2011)
Human RASSF7 regulates the microtubule cytoskeleton and is required for spindle formation, Aurora B activation and chromosomal congression during mitosis
Asha Recino et al.
BIOCHEMICAL JOURNAL (2010)
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
Ruriko Tanaka et al.
BLOOD (2010)
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state
Juergen den Hollander et al.
BLOOD (2010)
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC
Zhong-Zhe Lin et al.
BMC CANCER (2010)
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
Jennifer P. Arbitrario et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
The chromosome passenger complex is required for fidelity of chromosome transmission and cytokinesis in meiosis of mouse oocytes
Bedra Sharif et al.
JOURNAL OF CELL SCIENCE (2010)
The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma
Arihiro Aihara et al.
JOURNAL OF HEPATOLOGY (2010)
Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors
Shudong Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase
Nicholas D. Adams et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer
Christopher P. Gully et al.
MOLECULAR CANCER (2010)
Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
Dun Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization
O. Jameel Shah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Roger B. Cohen et al.
CLINICAL CANCER RESEARCH (2009)
The Topoisomerase I Poison CPT-11 Enhances the Effect of the Aurora B Kinase Inhibitor AZD1152 both In vitro and In vivo
Jayasree S. Nair et al.
CLINICAL CANCER RESEARCH (2009)
Deregulated Aurora-B induced tetraploidy promotes tumorigenesis
Hao G. Nguyen et al.
FASEB JOURNAL (2009)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors
Neeltje Steeghs et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity
Steven Howard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models
Mary Ann Hardwicke et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152
J. Guo et al.
PHARMACOGENOMICS JOURNAL (2009)
Aurora Kinase Inhibitor PHA-739358 Suppresses Growth of Hepatocellular Carcinoma In Vitro and in a Xenograft Mouse Model
Daniel Benten et al.
NEOPLASIA (2009)
Molecular basis of drug resistance in Aurora kinases
Fiona Girdler et al.
CHEMISTRY & BIOLOGY (2008)
Aurora-B Kinase Inhibitors for Cancer Chemotherapy
Sai-Ching Jim Yeung et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2008)
Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152
Y. Tao et al.
ONCOGENE (2008)
FBXW7/hCDC4 is a general tumor suppressor in human cancer
Shahab Akhoondi et al.
CANCER RESEARCH (2007)
AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo
Jing Yang et al.
BLOOD (2007)
Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells
Takaya Tsuno et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis
Robert W. Wilkinson et al.
CLINICAL CANCER RESEARCH (2007)
Homozygous mutation of AURKC yields large-headed polyploid spermatozoa and causes male infertility
Klaus Dieterich et al.
NATURE GENETICS (2007)
Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer
Guangying Qi et al.
VIRCHOWS ARCHIV (2007)
Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme
Weifen F. Zeng et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients
Barbara Vischioni et al.
MOLECULAR CANCER THERAPEUTICS (2006)
PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity
Chiara Soncini et al.
CLINICAL CANCER RESEARCH (2006)
The chromosomal passenger complex: guiding Aurora-B through mitosis
Gerben Vader et al.
JOURNAL OF CELL BIOLOGY (2006)
Targeting aurora kinases for the treatment of prostate cancer
Edmund Chun Yu Lee et al.
CANCER RESEARCH (2006)
Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation
P Chieffi et al.
PROSTATE (2006)
Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation
A Kanda et al.
ONCOGENE (2005)
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability
SL Smith et al.
BRITISH JOURNAL OF CANCER (2005)
Aurora kinases
VM Bolanos-Garcia
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Mechanism of aurora-B degradation and its dependency on intact KEN and A-boxes: Identification of an aneuploidy-promoting property
HG Nguyen et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Mechanism of Aurora B activation by INCENP and inhibition by Hesperadin
F Sessa et al.
MOLECULAR CELL (2005)
Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation
R Sorrentino et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Aurora B expression in normal testis and seminomas
P Chieffi et al.
JOURNAL OF ENDOCRINOLOGY (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
U Creutzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle
R Gassmann et al.
JOURNAL OF CELL BIOLOGY (2004)
The cellular geography of aurora kinases
M Carmena et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint
S Hauf et al.
JOURNAL OF CELL BIOLOGY (2003)
Crystal structure of aurora-2, an oncogenic serine/threonine kinase
GMT Cheetham et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mammalian aurora kinases
C Crosio et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis
SG Zeitlin et al.
JOURNAL OF CELL BIOLOGY (2001)
Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation
RR Adams et al.
JOURNAL OF CELL BIOLOGY (2001)
Drosophila Aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis
R Giet et al.
JOURNAL OF CELL BIOLOGY (2001)
Mitotic kinases as regulators of cell division and its checkpoints
EA Nigg
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Share Paper
